MedTrace Logo

Azacytidine Plus FLAG for Relapsed or Refractory AML

NCT02275663 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2015-01-06

No results posted yet for this study

Summary

The purpose of this phase 2 study is to test the efficacy of azacytidine given prior to fludarabine, cytarabine, and G-CSF for the treatment of relapsed or refractory acute myeloid leukemia.

Conditions

Interventions

DRUG

Azacytidine

DRUG

Fludarabine

DRUG

Cytarabine

DRUG

Filgrastim

G-CSF

Sponsors & Collaborators

  • King Fahad Medical City

    lead OTHER_GOV

Principal Investigators

  • Ibraheem H Motabi, MD · King Fahad Medical City

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-10-31
Completion
2018-10-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02275663 on ClinicalTrials.gov